BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Holmes JA, Rutledge SM, Chung RT. Direct-acting antiviral treatment for hepatitis C. The Lancet 2019;393:1392-4. [DOI: 10.1016/s0140-6736(18)32326-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Bello-Onaghise G, Wang G, Han X, Nsabimana E, Cui W, Yu F, Zhang Y, Wang L, Li Z, Cai X, Li Y. Antiviral Strategies of Chinese Herbal Medicine Against PRRSV Infection. Front Microbiol 2020;11:1756. [PMID: 32849384 DOI: 10.3389/fmicb.2020.01756] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
2 Ridruejo E, Pereson MJ, Flichman DM, Di Lello FA. Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions. World J Hepatol 2021; 13(9): 1069-1078 [PMID: 34630875 DOI: 10.4254/wjh.v13.i9.1069] [Reference Citation Analysis]
3 Teaima MH, Al-Nuseirat A, Abouhussein D, Badary OA, El-Nabarawi MA. Pharmaceutical policies and regulations of oral antiviral drugs for treatment of hepatitis C in Egypt-case study. J Pharm Policy Pract 2021;14:106. [PMID: 34915937 DOI: 10.1186/s40545-021-00389-6] [Reference Citation Analysis]
4 Soni S, Singh D, Aggarwal R, Veerapu NS. Enhanced fitness of hepatitis C virus increases resistance to direct-acting antivirals. J Gen Virol 2022;103. [PMID: 35133954 DOI: 10.1099/jgv.0.001699] [Reference Citation Analysis]
5 Hale AJ, Mathur S, Dejace J, Lidofsky SD. Statewide Assessment of the Hepatitis C Virus Care Cascade for Incarcerated Persons in Vermont. Public Health Rep 2022;:333549221077070. [PMID: 35264027 DOI: 10.1177/00333549221077070] [Reference Citation Analysis]
6 Carty PG, Fawsitt CG, Gillespie P, Harrington P, O'Neill M, Smith SM, Teljeur C, Ryan M. Population-Based Testing for Undiagnosed Hepatitis C: A Systematic Review of Economic Evaluations. Appl Health Econ Health Policy 2021. [PMID: 34870793 DOI: 10.1007/s40258-021-00694-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Buonaguro FM, Ascierto PA, Morse GD, Buonaguro L, Puzanov I, Tornesello ML, Bréchot C, Gallo RC. Covid-19: Time for a paradigm change. Rev Med Virol 2020;30:e2134. [PMID: 32618072 DOI: 10.1002/rmv.2134] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 11.0] [Reference Citation Analysis]
8 Shakeri A, Hayes KN, Gomes T, Tadrous M. Comparison of public and private payments for direct-acting antivirals (DAAs) across Canada. CanLivJ 2021;4:426-9. [DOI: 10.3138/canlivj-2020-0041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Surendran A, Bhalla A, Whyte MB. Improved diabetes control, allowing insulin cessation, after direct acting antiviral treatment (DAAT) of hepatitis C. BMJ Case Rep 2022;15:e243491. [PMID: 35450872 DOI: 10.1136/bcr-2021-243491] [Reference Citation Analysis]
10 Pipe SW, Kruse-Jarres R, Mahlangu JN, Pierce GF, Peyvandi F, Kuebler P, De Ford C, Sanabria F, Ko RH, Chang T, Hay CRM. Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database. J Thromb Haemost 2021;19 Suppl 1:21-31. [PMID: 33331042 DOI: 10.1111/jth.15186] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Liu CH, Lu CH, Wong SH, Lin LT. Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects. Front Immunol 2020;11:616595. [PMID: 33613542 DOI: 10.3389/fimmu.2020.616595] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Shakeri A, Konstantelos N, Chu C, Antoniou T, Feld J, Suda KJ, Tadrous M. Global Utilization Trends of Direct Acting Antivirals (DAAs) during the COVID-19 Pandemic: A Time Series Analysis. Viruses 2021;13:1314. [PMID: 34372520 DOI: 10.3390/v13071314] [Reference Citation Analysis]
13 Ghosh A, Romani S, Kottilil S, Poonia B. Lymphocyte Landscape after Chronic Hepatitis C Virus (HCV) Cure: The New Normal. Int J Mol Sci. 2020;21. [PMID: 33050486 DOI: 10.3390/ijms21207473] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Khan S, Soni S, Veerapu NS. HCV Replicon Systems: Workhorses of Drug Discovery and Resistance. Front Cell Infect Microbiol 2020;10:325. [PMID: 32714881 DOI: 10.3389/fcimb.2020.00325] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Frazzoni L, Sikandar U, Metelli F, Sadalla S, Mazzella G, Bazzoli F, Fuccio L, Azzaroli F. Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis. J Clin Med 2021;10:1694. [PMID: 33920785 DOI: 10.3390/jcm10081694] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Kumar P, Kulkarni A, Sharma M, Rao PN. Repurposing Hepatitis C Direct-Acting Antivirals Against COVID-19. J Clin Exp Hepatol 2021;11:273-5. [PMID: 33071519 DOI: 10.1016/j.jceh.2020.10.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Tonnerre P, Wolski D, Subudhi S, Aljabban J, Hoogeveen RC, Damasio M, Drescher HK, Bartsch LM, Tully DC, Sen DR, Bean DJ, Brown J, Torres-Cornejo A, Robidoux M, Kvistad D, Alatrakchi N, Cui A, Lieb D, Cheney JA, Gustafson J, Lewis-Ximenez LL, Massenet-Regad L, Eisenhaure T, Aneja J, Haining WN, Chung RT, Hacohen N, Allen TM, Kim AY, Lauer GM. Differentiation of exhausted CD8+ T cells after termination of chronic antigen stimulation stops short of achieving functional T cell memory. Nat Immunol 2021;22:1030-41. [PMID: 34312544 DOI: 10.1038/s41590-021-00982-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]